Pharmacy Grand Rounds 
Going Viral: The Role of Remdesivir in COVID-19

• ACPE Universal Activity Number (UAN): JA0000238-0000-21-004-L01-P
• Session Type: Knowledge-based
• CE Credits: A maximum of 0.75 contact hour (0.075 CEU) for the following: 
  • AAPA Category 1 CME Credits
  • ACPE
  • AMA PRA Category 1 Credits™
  • ANCC

• Session Fee: Free for Mayo Clinic staff

SESSION LOCATIONS

Live Session: (11:00am - 11:45am CST) 

Until further notice, learners must watch Pharmacy Grand Rounds live via the web by going to the Video Exchange and selecting “Pharmacy Grand Rounds” in the “Streaming Now” section.

Participants may attend by viewing: Live Webcast
Video Recording - access two weeks after session date

COURSE DESCRIPTIONIn the past year multiple different medications have been evaluated for use in COVID-19. Remdesivir is an antiviral that showed promise in SARS-CoV-2 infections early in 2020 then was subsequently FDA-approved for its use in COVID-19 in late 2020. This presentation will review the data behind remdesivir’s use and describe an ideal patient population for remdesivir.

LEARNING OBJECTIVES
At the conclusion of this knowledge-based CE session, participants should be able to:

• Describe remdesivir’s mechanism of action against SARS-CoV-2
• Identify optimal adult patient populations for remdesivir
• Outline future directions for remdesivir in COVID-19 treatment

Session Announcement.pdf

PowerPoint.pdf

FACULTY INFORMATION

Jen L. Adema, PharmD, MBA
PGY2 Internal Medicine Pharmacy Resident
Mayo Clinic Hospital - Rochester, MN

Jen received Doctor of Pharmacy and Master of Business Administration degrees from Campbell University in Buies Creek, NC.  She completed a PGY1 residency at Vidant Medical Center in Greenville, NC and is the current PGY2 Internal Medicine Pharmacy Resident at Mayo Clinic Hospital – Rochester. Dr. Adema’s clinical practice interests include infectious diseases, cardiology, and precepting. 

DISCLOSURE STATEMENTS
As a provider accredited by Joint Accreditation Interprofessional Continuing Education, Mayo Clinic College of Medicine and Science (Mayo Clinic School of CPD) must ensure balance, independence, objectivity and scientific rigor in its educational activities. Course Director(s), Planning Committee Members, Faculty, and all others who are in a position to control the content of this educational activity are required to disclose all relevant financial relationships with any commercial interest related to the subject matter of the educational activity. Safeguards against commercial bias have been put in place. Faculty also will disclose any off label and/or investigational use of pharmaceuticals or instruments discussed in their presentation. Disclosure of these relevant financial relationships will be published in activity materials so those participants in the activity may formulate their own judgments regarding the presentation.

Listed below are individuals with control of the content of this program:

The faculty report the following relationships:

• Jen L. Adema, PharmD, MBA
  • Declares no financial relationship(s) pertinent to this session
  • Declares off-label use of devices and medications will be discussed during this presentation, including:
    • Baricitinib
    • Interferon beta-1a

Course Director and Planning Committee Members declare no relevant financial relationship(s) pertinent to this session. 

Members include:

• Jennifer Elmer, DNP, APRM, CCNS, FCCM
• Michael Huckabee, MPAS, PA-C, PhD
• Sarah Jane Kotval, BSW
• Wayne (Nick) Nicholson, MD, PharmD, BCPS
• Garrett Schramm, PharmD, BCPS
• Lee Skrupky, PharmD, BCPS
• Brenda Stellmaker